In a groundbreaking move, Prime Medicine, Inc. (Nasdaq: PRME), a leading biotechnology company dedicated to revolutionizing the field of genetic therapies, has announced the pricing of an underwritten upsized public offering. This strategic move underscores Prime Medicine’s commitment to delivering a new class of differentiated one-time curative genetic therapies.
The public offering includes 19,200,001 shares of Prime Medicine’s common stock, priced at $6.25 per share. Additionally, the company will offer pre-funded warrants to certain investors, allowing them to purchase 3,200,005 shares of common stock at a public offering price of $6.24999 per pre-funded warrant. It is important to note that the exercise price for each pre-funded warrant is $0.00001 less than the per-share public offering price.
To provide investors with more opportunities, Prime Medicine has also granted the underwriters a 30-day option to purchase up to an additional 3,360,000 shares of its common stock. The expected gross proceeds from the offering, before deducting underwriting discounts, commissions, and offering expenses, are estimated to be approximately $140.0 million. It is worth mentioning that this figure excludes any potential exercise of the underwriters’ option to purchase additional shares.
All of the shares and pre-funded warrants offered in the public offering will be sold by Prime Medicine. The closing of the offering is scheduled to occur on or about February 20, 2024, subject to the satisfaction of customary closing conditions.
Prime Medicine’s shares are currently trading at a modest 21.7% above their 52-week low. However, the company’s financial statement reveals a cumulative net loss of $-13 million during the 12 months ending in the third quarter of 2023, resulting in a negative return on equity (ROE) of -10.34%. It is noteworthy that within the highly competitive Biotechnology & Pharmaceuticals industry, there are 16 other companies with a higher return on equity.
This recent public offering indicates Prime Medicine’s determination to gather additional funds to fuel its research and development efforts, potentially aiming towards overcoming the financial setbacks. Despite the challenging financial performance, the company remains optimistic about its pioneering work and the future of advanced genetic therapies.
Comments